RHAGe System
Rapid Human Antibody Generation
Rapid Human Antibody Generation or RHAGe is an end-to-end system for the discovery and commercialization of fully-human monoclonal antibody (mAb) drug candidates. The system integrates proprietary in-house and external discovery, development, and manufacturing technologies.
Central to RHAGe is BioFactura’s VeriCyte Discovery Platform for the isolation of fully human therapeutic mAbs from human B lymphocytes. Complementing this technology, is the Company’s StableFast Biomanufacturing Platform, which utilizes the FDA-approved NS0 cell line, and allows the rapid development and production of lead mAb candidates. Other elements of the RHAGe system include the Hu-M Humanized Mouse (HuMurine Technologies) and human hybridoma immortalization (Ben Gurion University) technologies.
The RHAGe drug development system offers companies developing monoclonal antibody-based drugs shorter time-to-market, reduced costs, and high potency and fidelity drug candidates. The RHAGe system is also well suited to serve the high-growth biosimilars and biobetters markets.
